CN113166151B - 经取代的黄嘌呤衍生物 - Google Patents
经取代的黄嘌呤衍生物 Download PDFInfo
- Publication number
- CN113166151B CN113166151B CN201980081737.1A CN201980081737A CN113166151B CN 113166151 B CN113166151 B CN 113166151B CN 201980081737 A CN201980081737 A CN 201980081737A CN 113166151 B CN113166151 B CN 113166151B
- Authority
- CN
- China
- Prior art keywords
- mmol
- mixture
- esi
- hplc
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212060.0 | 2018-12-12 | ||
| EP18212060 | 2018-12-12 | ||
| PCT/EP2019/084375 WO2020120450A1 (en) | 2018-12-12 | 2019-12-10 | Substituted xanthine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113166151A CN113166151A (zh) | 2021-07-23 |
| CN113166151B true CN113166151B (zh) | 2023-12-01 |
Family
ID=64665184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980081737.1A Active CN113166151B (zh) | 2018-12-12 | 2019-12-10 | 经取代的黄嘌呤衍生物 |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12064917B2 (en) | 2012-11-21 | 2024-08-20 | Stratasys, Inc. | Method for printing three-dimensional parts with cyrstallization kinetics control |
| IL283768B2 (en) * | 2018-12-12 | 2024-05-01 | Boehringer Ingelheim Int | Xanthine histories are transmuted |
| KR20250141831A (ko) * | 2023-02-08 | 2025-09-29 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 잔틴계 화합물 및 이의 용도 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105143229A (zh) * | 2013-03-15 | 2015-12-09 | 海德拉生物科学有限公司 | 取代的黄嘌呤及其使用方法 |
| WO2019011802A1 (en) * | 2017-07-11 | 2019-01-17 | Boehringer Ingelheim International Gmbh | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3180340B1 (en) | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| IL283768B2 (en) * | 2018-12-12 | 2024-05-01 | Boehringer Ingelheim Int | Xanthine histories are transmuted |
-
2019
- 2019-12-10 IL IL283768A patent/IL283768B2/en unknown
- 2019-12-10 AU AU2019396499A patent/AU2019396499B2/en not_active Ceased
- 2019-12-10 JP JP2021533340A patent/JP7502299B2/ja active Active
- 2019-12-10 WO PCT/EP2019/084375 patent/WO2020120450A1/en not_active Ceased
- 2019-12-10 PL PL19820718.5T patent/PL3894410T3/pl unknown
- 2019-12-10 HU HUE19820718A patent/HUE064908T2/hu unknown
- 2019-12-10 ES ES19820718T patent/ES2964630T3/es active Active
- 2019-12-10 PH PH1/2021/551345A patent/PH12021551345A1/en unknown
- 2019-12-10 KR KR1020217021875A patent/KR102877857B1/ko active Active
- 2019-12-10 EA EA202191588A patent/EA202191588A1/ru unknown
- 2019-12-10 BR BR112021008316-2A patent/BR112021008316A2/pt unknown
- 2019-12-10 EP EP19820718.5A patent/EP3894410B1/en active Active
- 2019-12-10 CN CN201980081737.1A patent/CN113166151B/zh active Active
- 2019-12-10 MX MX2021007019A patent/MX2021007019A/es unknown
- 2019-12-10 DK DK19820718.5T patent/DK3894410T3/da active
- 2019-12-11 US US16/710,887 patent/US11198696B2/en active Active
- 2019-12-12 TW TW108145593A patent/TWI825243B/zh active
-
2021
- 2021-06-09 CL CL2021001509A patent/CL2021001509A1/es unknown
- 2021-11-10 US US17/523,316 patent/US20220177479A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105143229A (zh) * | 2013-03-15 | 2015-12-09 | 海德拉生物科学有限公司 | 取代的黄嘌呤及其使用方法 |
| WO2019011802A1 (en) * | 2017-07-11 | 2019-01-17 | Boehringer Ingelheim International Gmbh | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Also Published As
| Publication number | Publication date |
|---|---|
| PL3894410T3 (pl) | 2024-03-18 |
| HUE064908T2 (hu) | 2024-04-28 |
| ES2964630T3 (es) | 2024-04-08 |
| BR112021008316A2 (pt) | 2021-08-03 |
| KR20210102955A (ko) | 2021-08-20 |
| US11198696B2 (en) | 2021-12-14 |
| CN113166151A (zh) | 2021-07-23 |
| DK3894410T3 (da) | 2023-11-27 |
| IL283768A (en) | 2021-07-29 |
| TWI825243B (zh) | 2023-12-11 |
| JP7502299B2 (ja) | 2024-06-18 |
| CA3119229A1 (en) | 2020-06-18 |
| KR102877857B1 (ko) | 2025-10-29 |
| EP3894410B1 (en) | 2023-10-11 |
| EP3894410A1 (en) | 2021-10-20 |
| TW202039495A (zh) | 2020-11-01 |
| US20200190093A1 (en) | 2020-06-18 |
| MX2021007019A (es) | 2021-09-10 |
| IL283768B1 (en) | 2024-01-01 |
| US20220177479A1 (en) | 2022-06-09 |
| WO2020120450A1 (en) | 2020-06-18 |
| CL2021001509A1 (es) | 2021-12-17 |
| PH12021551345A1 (en) | 2022-05-11 |
| AU2019396499A1 (en) | 2021-05-27 |
| AU2019396499B2 (en) | 2024-10-10 |
| IL283768B2 (en) | 2024-05-01 |
| JP2022512373A (ja) | 2022-02-03 |
| EA202191588A1 (ru) | 2021-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7114702B2 (ja) | 新規置換キサンチン誘導体 | |
| CA3145868A1 (en) | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxi n (atx) modulators for the treatment of inflammatory airway or fibrotic diseases | |
| TWI825243B (zh) | 新穎之經取代黃嘌呤衍生物 | |
| CA3146439A1 (en) | 1-(6-(methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway diseases | |
| EP3894409B1 (en) | Substituted xanthine derivatives | |
| CA3071074A1 (en) | New propanamine derivatives for treating pain and pain related conditions | |
| TW201504227A (zh) | 環狀胺基甲基嘧啶衍生物 | |
| CA3119229C (en) | Substituted xanthine derivatives | |
| EA043969B1 (ru) | Замещенные ксантиновые производные | |
| JP2022509014A (ja) | 疼痛及び疼痛に関連する状態を処置するための新規なアルコキシアミノピリジン誘導体 | |
| BR112020021569B1 (pt) | Composto e uso do mesmo para tratamento de leucemia aguda | |
| HK40025200B (en) | Substituted xanthine derivatives | |
| HK40025200A (en) | Substituted xanthine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |